Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer

  title={Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer},
  author={Eugenia E. Calle and Clark W. Jr. Heath and Ralph J. Coates and Jonathan M. Liff and Silvia Franceschi and Renato Talamini and Nivat Chantarakul and Suporn Koetsawang and Duangdao Rachawat and A. Morabia and Louise Schuman and Walter F. Stewart and Moys{\'e}s Szklo and Chris Bain and F D Schofield and Victor Siskind and P. Band and Andrew J Coldman and Richard P. Gallagher and T. Greg Hislop and P. Yang and Stephen W. Duffy and Laurence K. Kolonel and A. M Y Nomura and Mark W. Oberle and Howard W. Ory and Herbert B. Peterson and Hoyt G. Wilson and Phyllis A. Wingo and K. Ebeling and Dieter Kunde and P. Nishan and Graham A. Colditz and Nicholas G. Martin and Tieng Pardthaisong and Suporn Silpisornkosol and Choti Theetranont and Banpot Boosiri and Supawat Chutivongse and Prasarn Jimakorn and Pramuan Virutamasen and Chansuda Wongsrichanalai and A. J. McMichael and T. E. Rohan and Marianne Ewertz and Carle Paul and David C. G. Skegg and G. F. S. Spears and Peter Boyle and M. Evstifeeva and Janet R. Daling and W. B. Hutchinson and Kathleen E. Malone and Elizabeth A. Noonan and Janet L. Stanford and David B. Thomas and Noel S. Weiss and Emily White and Nadine Andrieu and A. Br{\`a}mond and Franqois Clavel and B{\'e}atrice Gairard and Jacques Lansac and Libero Della Piana and Robert Renaud and S. R P Fine and H{\'e}ctor Rodriguez Cuevas and Patricia Reyna Ontiveros and Antonio Palet and S. B. Salazar and N. Aristizabel and Alvaro Cuadros and Agnes Bachelot and M. G. L{\^e} and Judith Deacon and Julian Peto and C. N. Taylor and Esther Alfandary and Baruch Modan and Elaine Ron and Gary D. Friedman and Robert A. Hiatt and Tim Bishop and J. Kosmelj and Maja Primic‐Žakelj and Bo{\vz}ena Ravnihar and J. Stare and W. Larry Beeson and Graeme Fraser and Richard D. Bulbrook and Jack M Cuzick and Ian S. Fentiman and John L. Hayward and D. Y. Wang and Robert L. Hanson and M. C. Leske and Martin Christopher Mahoney and P. C. Nasca and Andre O. Varma and A. L. Weinstein and Torgil R. M{\"o}ller and Hampus Olsson and Jonas Ranstam and R. Alexandra Goldbohm and Piet A. Brandt and R. A. Apelo and Jose Baens and J. R. de la Cruz and B. Javier and L. B. Lacaya and Corazon A Ngelangel and C. La Vecchia and Eva Negri and Ettore Marubini and Monica Ferraroni and Mariette Gerber and Sylvia Richardson and Claire S{\'e}gala and David Gatei and Patrick Kenya and Alfred Kungu and J. G. Mati and Louise A. Brinton and Robert N Hoover and Catherine Schairer and Robert Spirtas and H. P. Lee and Matti A Rookus and F. E. van Leeuwen and J. A. Schoenberg and Marilie D. Gammon and E Aileen Clarke and Louise J. Jones and Klim McPherson and Andrew Neil and M. P. Vessey and David G R Yeates and Valerie Beral and Diana Bull and Barbara Crossley and Carol Hermon and S. Jones and Timothy J. Key and C. Lewis and Gillian K Reeves and Rory Collins and Richard Doll and Richard Peto and P. Hannaford and Clifford R. Kay and Luis Rosero-Bixby and Jian-Min Yuan and Hsin-Yen Wei and Tao Yun and Cheng Zhiheng and Geoffrey Berry and Joan Cooper Booth and Tatiana Jelihovsky and Robert Maclennan and R. Shearman and Q. S. Wang and Cornelia J. Baines and Anthony B Miller and Claus Wall and Eiliv Lund and Helge Stalsberg and A. Dabancens and Luis Mart{\'i}nez and Ramiro Molina and Oriana Salas and Freda E. Alexander and B. S. Hulka and Clair E. D. Chilvers and Leslie Bernstein and Robert W. Haile and Annlia Paganini-Hill and Malcolm C. Pike and Ronald K. Ross and Giske Ursin and Mimi C. Yu and M. P. Longnecker and Polly A. Newcomb and T. M N Farley and Susan Holck and Olav Meirik and Hans-Olov Adami and R. Bergkvist and Ingemar R. Persson and Fabio Levi and Kiyohiko Mabuchi and Dale L Preston and Klea Katsouyanni and Antonia Trichopoulou and D. Trichopoulos and Leif Bergkvist},
  journal={The Lancet},

Figures and Tables from this paper

Review: use of hormone replacement therapy in the past 5 years is associated with an increased risk of breast cancer

An increase in the risk of breast cancer was associated with age at diagnosis >60 years, no family history, white race, ever having smoked, and natural menopause, which decreased with increasing weight and increasing body mass index.

Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe

The Danish Nurse Cohort was established in 1993, where all female nurses aged 45 years and above received a mailed questionnaire, and a total of 19,898 women returned the questionnaire (86%).

Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study

It is confirmed that HRT increases the risk of developing breast cancer in women aged 50 years or more, and no material risk difference was observed among the various HRT-regimens.

Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years.

  • J. DalingK. Malone R. Spirtas
  • Medicine
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • 2003
The tumors of women with breast cancer who use HRT have some better prognostic factors than those of women who have not used HRT, but this advantage may be due to the racial and age differences in those who use the various regimens of HRT and the effect of more frequent screening among HRT users, leading to earlier diagnosis.

Oral contraceptives, hormone replacement therapy and breast cancer risk: A cohort study of 16 928 women 48 years and older

The results of the population-based cohort study do not support the notion that former OC use increases breast cancer risk among HRT users, on the contrary there was an indication of a slightly lower risk in former OC users, restricted to current, long-term EP-HRT users.

Breast cancer and hormone replacement therapy: putting the risk into perspective

The CGHFBC reanalysis did not show a substantial difference in breast cancer risk between the majority using estrogen alone and the small minority using estrogen plus progestin, but Swedish studies and the recent American studies suggest that the risk increase could be higher with the addition of a progesterone-like effects, compared with estrogen-only use.



Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women.

Replacement hormone use was not associated with breast cancer risk in women who had ever undergone this treatment, and the results do not support a hypothesized effect of combined progestin and estrogen use on the risk of breast cancer.

Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.

The use of estrogen with progestin HRT does not appear to be associated with an increased risk of breast cancer in middle-aged women, and future investigations must assess whether breast cancer incidence is altered many years after estrogen-progestin H RT has been initiated, particularly among long-term users.

The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy.

Overall, the risk of breast cancer did not appear to increase appreciably with increasing ERT duration or latency, even for durations and latencies of 20 years or longer.

Prospective study of exogenous hormone use and breast cancer in seventh‐day adventists

Exogenous hormone use as either oral contraceptives (OC) or hormone replacement therapy (HRT) was evaluated in reference to subsequent breast cancer risk in a cohort study of 20,341 Seventh‐day

Hormone replacement treatment and breast cancer risk: a cooperative Italian study.

The absence of a strong association between HRT and breast cancer risk is confirmed, although the risk estimate was above unity for women who had used HRT for 5 years or longer, and the risk was significantly elevated in the short to medium term after use, particularly for long-term use.

Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study.

The results provide evidence against an increase in risk among women who used unopposed conjugated estrogens for less than 15 years and for recent users; for women with durations of at least 15 years, an increase could not be ruled out.

Exogenous estrogens and other factors in the epidemiology of breast cancer.

In a hospital-based case-control study of the epidemiology of breast cancer undertaken in Connecticut from 1977 to 1979, there was no evidence of an increase in risk for breast cancer among women who

Breast cancer and estrogen replacement therapy.

Estrogen use and breast cancer interaction with body mass

Data suggest that relative body weight is an important modifier of the effect of exogenous estrogens on breast cancer biology, and among estrogen users, the relative risk of breast cancer was strikingly influenced by the ponderosity of the subjects.